iRadimed (NASDAQ:IRMD) Sees Strong Trading Volume – Still a Buy?

Shares of iRadimed Corporation (NASDAQ:IRMD) saw strong trading volume on Wednesday . 48,762 shares changed hands during trading, a decline of 45% from the previous session’s volume of 88,590 shares.The stock last traded at $88.7150 and had previously closed at $87.36.

Analyst Ratings Changes

Several analysts have recently commented on the company. Freedom Capital upgraded iRadimed to a “strong-buy” rating in a report on Thursday, April 2nd. Weiss Ratings upgraded iRadimed from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, May 6th. Lake Street Capital restated a “buy” rating and set a $120.00 target price on shares of iRadimed in a report on Wednesday, February 11th. Finally, Roth Mkm restated a “buy” rating and set a $120.00 target price on shares of iRadimed in a report on Tuesday, February 10th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $120.00.

iRadimed Stock Up 2.0%

The firm has a market cap of $1.14 billion, a price-to-earnings ratio of 48.68 and a beta of 0.90. The business’s fifty day moving average is $93.22 and its two-hundred day moving average is $94.91.

iRadimed (NASDAQ:IRMD) last issued its quarterly earnings results on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.03. The business had revenue of $21.98 million during the quarter, compared to analyst estimates of $21.32 million. iRadimed had a net margin of 27.36% and a return on equity of 24.48%. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. Research analysts forecast that iRadimed Corporation will post 1.52 EPS for the current year.

iRadimed Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 29th. Shareholders of record on Friday, May 15th will be issued a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Friday, May 15th. iRadimed’s payout ratio is currently 43.72%.

Insiders Place Their Bets

In other news, CEO Roger E. Susi sold 4,411 shares of the stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $83.92, for a total value of $370,171.12. Following the transaction, the chief executive officer owned 2,180,000 shares of the company’s stock, valued at $182,945,600. This represents a 0.20% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 60,000 shares of company stock worth $5,661,603. Insiders own 36.80% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in IRMD. Farther Finance Advisors LLC boosted its stake in iRadimed by 827.1% during the 4th quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock worth $43,000 after acquiring an additional 397 shares during the last quarter. CWM LLC boosted its stake in iRadimed by 62.2% during the 3rd quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 211 shares during the last quarter. Quarry LP bought a new position in iRadimed during the 3rd quarter worth approximately $40,000. State of Alaska Department of Revenue bought a new position in iRadimed during the 3rd quarter worth approximately $47,000. Finally, Tower Research Capital LLC TRC boosted its stake in iRadimed by 191.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after acquiring an additional 495 shares during the last quarter. Institutional investors and hedge funds own 92.34% of the company’s stock.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.